re: Ann: Supplemental Information for Quarter... A few takeaways from the Q&A session.
CANVAS
Approx 70 patients already randomised will remain on the trial and 210 new recruitments of 2nd line remission patients.
Expect to have the results for final "proof of concept" by end of 2016.
PANCREATIC
To be conducted mainly in Europe, from the Leipzig operation, in order to maximise the reimbursement from Saxony Bank rebate.
LICENSING PARTNERSHIPS
ML pretty cagey about discussing what other geographical territories they are currently in discussions for.
Ann: Supplemental Information for Quarterly Confe, page-3
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $400.0M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.3¢ | 27.0¢ | $1.034M | 3.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 98156 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 85523 | 9 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |